Castle Biosciences (CSTL) Share-based Compensation (2018 - 2026)
Castle Biosciences' Share-based Compensation history spans 8 years, with the latest figure at $11.4 million for Q4 2025.
- On a quarterly basis, Share-based Compensation changed 0.29% to $11.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.9 million, a 8.8% decrease, with the full-year FY2025 number at $45.9 million, down 8.8% from a year prior.
- Share-based Compensation hit $11.4 million in Q4 2025 for Castle Biosciences, down from $12.1 million in the prior quarter.
- Over the last five years, Share-based Compensation for CSTL hit a ceiling of $13.5 million in Q1 2023 and a floor of $4.8 million in Q2 2021.
- Historically, Share-based Compensation has averaged $10.3 million across 5 years, with a median of $11.3 million in 2025.
- Biggest five-year swings in Share-based Compensation: soared 211.54% in 2021 and later decreased 14.96% in 2025.
- Tracing CSTL's Share-based Compensation over 5 years: stood at $6.9 million in 2021, then surged by 44.84% to $9.9 million in 2022, then rose by 18.94% to $11.8 million in 2023, then decreased by 3.08% to $11.4 million in 2024, then decreased by 0.29% to $11.4 million in 2025.
- Business Quant data shows Share-based Compensation for CSTL at $11.4 million in Q4 2025, $12.1 million in Q3 2025, and $11.2 million in Q2 2025.